向HPK1抑制中性粒细胞的反应,以减轻中风后的肺和脑损伤
Tingting Zhang1,2, Ying Sun1,2, Jing Xia1,2
1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
EMBO molecular medicine
|April 1, 2025
概括
造血原体激酶1 (HPK1) 驱动中性粒细胞过活化和动员,在急性缺血性中风 (AIS) 后的结果恶化. 抑制HPK1可以改善中风后的肺和大脑功能.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- 中性粒细胞导致急性缺血性中风 (AIS) 后的不良结果和呼吸系统问题.
- 控制中性粒细胞反应的分子机制及其在中风后并发症中的作用尚未完全理解.
研究的目的:
- 为了研究血液生成原生激酶1 (HPK1) 在中性粒细胞反应和动员中的作用.
- 为了确定HPK1在AIS后的肺和脑损伤中的参与.
主要方法:
- 研究了HPK1在脂聚糖诱导的中性粒细胞激活中的作用.
- 在小鼠中分析了HPK1对中性粒细胞动员和AIS后透的影响.
- 评估HPK1抑制对全身炎症和器官功能的影响.
主要成果:
- 通过NF-κB/STAT3/p38-MAPK通路和气皮D裂变,HPK1调解中性粒细胞的过活化.
- 在AIS后,HPK1促进了CXCR2高中性粒细胞的调动.
- 在小鼠中,HPK1抑制减少了中性粒细胞的透,细胞外陷聚合,全身炎症,改善了肺和神经功能.
结论:
- HPK1增强了中性粒细胞的动员和反应,加剧了中风后的炎症和组织损伤.
- 在AIS后,HPK1是改善神经和肺部结果的潜在治疗标.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...